drugset
drugset / Trial / NCT03735810

Safety and Tolerability Study of LBS-008 in Healthy Adult Subjects After Single and Multiple Doses

NCT03735810 ↗

Phase 1 Completed 71 enrolled RBP4 Pty Ltd Belite Bio, Inc · collab
RandomizedSequentialDouble-blindBasic science

Summary

This is a single center, randomized, double-blind, placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) study is planned to assess safety, pharmacokinetics (PK), and pharmacodynamics of LBS-008 in healthy adult volunteers.

Timeline

Start
2018-11-15
Primary completion
2019-09-16
Completion
2019-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Tinlarebant Small molecule 5 mg Oral
Subject Tinlarebant Small molecule 10 mg Oral
Subject Tinlarebant Small molecule 12 mg Oral
Subject Tinlarebant Small molecule 25 mg Oral
Subject Tinlarebant Small molecule 50 mg Oral
Subject Tinlarebant Small molecule 100 mg Oral
Subject Tinlarebant Small molecule 200 mg Oral
Subject Tinlarebant Small molecule 400 mg Oral

Indications

No indication recorded.